The consequences of *Campylobacter* infection

Sarah J O'Brien^{1,2}

1 = Department of Public Health and Policy, Institute of Psychology, Health and Society, University of Liverpool, UK

2 = NIHR Health Protection Research Unit in Gastrointestinal Infections, UK

Corresponding Author = Sarah J O'Brien

NIHR Health Protection Research Unit in Gastrointestinal Infections, UK

The Farr Institute@HeRC

University of Liverpool

2nd Floor, Block F Waterhouse Buildings

1-5 Brownlow Street

Liverpool

L69 3GL

Tel: +44 151 795 8301

E-mail: s.j.obrien@liverpool.ac.uk

Abstract

Purpose of review

The purpose of this review is to provide an update on the clinical, public health and economic consequences of *Campylobacter* infection.

Recent findings

Campylobacter is a leading bacterial cause of food-related illness. Its importance is enhanced by the chronic sequelae that can result from acute infection. Recent advances include a new clinical classification system for neurological sequelae with the aim of speeding accurate diagnosis and appropriate treatment, a better understanding of the mechanisms underlying post-infectious functional gastrointestinal disorders, the emergence of *C. concisus* and *C. showae* as potential aetiological agents in inflammatory bowel disease, a new mechanism for antimicrobial resistance in campylobacters and a better appreciation of the economic costs.

Summary

Campylobacter infection is very common and can lead to serious chronic sequelae and considerable personal, healthcare and societal costs.

Key Words

Campylobacter, foodborne disease, gastroenteritis, Guillain-Barré syndrome, Miller Fisher syndrome, irritable bowel syndrome, reactive arthritis

Abbreviations

aHR

aRR

Bv.

CI

DALY

ELISA

FGID

GBS

HUS

IBD

IBS

IgA

IgG

IVIg

MFS

MLST

P-OR

QoL

ReA

RT-PCR

Subsp.

Introduction

Since its first identification as a human pathogen in the 1970s *Campylobacter* has emerged as a leading cause of acute gastroenteritis worldwide. Clinically relevant organisms include *Campylobacter jejuni* and *C. coli*, which are the major pathogens, but several species are recognised causes of illness in humans [1•] (Table 1).

Clinical consequences

Acute enteritis

Campylobacter jejuni is among the most frequent causes of bacterial gastroenteritis globally [2-4••]. Using multilocus sequence typing (MLST) more than 8,300 *C. jejuni* sequence types (STs) have been described [5••]. Although generally considered to cause mild and self-limiting acute enteritis, in a recently completed retrospective cohort study in Sweden more than a quarter (27%) of stool culture positive *Campylobacter* cases were admitted to hospital [6•]. The majority (92%) of the laboratory-confirmed cases were admitted because of severe enteritis or colitis. There was a statistically significant 14-fold increase in risk of hospital admission for people with co-morbidities. People infected with *C. jejuni* ST-257 were twice as likely to be admitted to hospital. This study serves as a timely reminder that *C. jejuni* acute enteritis can be severe.

Chronic sequelae

As well as causing very unpleasant acute symptoms, *Campylobacter* infection is also associated with various chronic sequelae although the evidence for an association is stronger for some conditions than others. *Campylobacter* infection has been implicated in the subsequent development of reactive arthritis (ReA), Guillain-Barré syndrome (GBS) and Miller Fisher syndrome (MFS), haemolytic uraemic syndrome (HUS), inflammatory bowel disease (IBD) and functional gastrointestinal disorders (FGID). In a recent systematic review and meta-analysis of 31 observational studies the proportion of *Campylobacter* cases developing chronic sequelae was estimated. The proportion of *Campylobacter*

cases that went on to develop ReA was 2.86% (95% CI 1.40% - 5.61%), IBS was 4.01% (95% CI 1.41% - 10.88%) and GBS was 0.07% (95% CI 0.03%- 0.15%) [7•]. Given the overall incidence of *Campylobacter* infection (see below), these estimates suggest that a considerable number of *Campylobacter* cases can develop chronic sequelae but caution is required when interpreting the results because of high heterogeneity between studies.

Reactive Arthritis

Reactive arthritis (ReA), formerly known as Reiter's Syndrome, is a post-infectious spondyloarthropathy, which occurs around two to four weeks after gastrointestinal or genitourinary infections. The pain associated with ReA occurs most often in the knees, ankles and feet. In a systematic review using stringent criteria to define diarrhoea-associated ReA the weighted mean incidence of reactive arthritis following *Campylobacter* infection was 9 per 1,000 cases [8]. Further evidence for the contribution of *Campylobacter* infection to subsequent ReA comes from sero-prevalence data. Using an optimised ELISA assay for diagnosing a previous *Campylobacter* infection around 53% (44-62%) of ReA cases demonstrated *Campylobacter* sero-positivity (OMP18 and P39 for IgA and in the P39-antigen for IgG) [9]. Polymorphisms in the interleukin-18 and interferon-gamma genes appear to be associated with the development of *Campylobacter*-associated ReA [10]. Symptoms of ReA usually disappear completely within six months. However, in 10–20% of people the symptoms persist beyond six months although it is said that only a few people develop an ongoing arthritis beyond 12 months requiring longer-term treatment. Finally, antibiotic treatment does not appear to improve the outcome in ReA [11].

Guillain-Barré Syndrome

The most severe late consequence of *Campylobacter* infection is Guillain-Barré syndrome (GBS), which is the most frequent cause of acute flaccid symmetrical weakness of the limbs and absence of deep tendon reflexes [12]. The incidence of post-*Campylobacter* GBS is estimated to be between 1 in

1,000 and 1 in 5,000 cases. It is characterised initially by tingling in the toes, feet and legs, and the fingers, hands and arms. This is followed by ascending muscle weakness and paralysis (not to be confused with the descending paralysis of botulism). Symptoms of GBS can progress very rapidly. The majority of people reach the stage of greatest weakness within the first 2 weeks after symptoms first appear, and by the third week 90% of patients are at their weakest. Approximately 30% of patients with GBS have persisting weakness after 3 years. Around 3% can experience a relapse of muscle weakness and tingling sensations many years after the original episode.

The heterogeneity of presenting symptoms presents a considerable challenge in the initial clinical diagnosis of GBS. In a retrospective review of 69 GBS patients presenting to emergency rooms in Texas atypical clinical signs and symptoms led to delayed diagnosis [13]. In that study, neuropathic pain and the presence of intact deep tendon reflexes were significantly associated with delayed GBS diagnosis. Patients who were assessed by a neurologist during the initial visit experienced significantly better clinical outcomes. However, patients in whom GBS was not suspected during the initial neurology assessment were significantly more likely to need intubation and to have residual weakness at the time of discharge from hospital [13].

The mechanism of neural damage involves molecular mimicry between *C. jejuni* and human peripheral nerve proteins [14]. It is known that sialylated lipo-oligosaccharides (LOS) of *C. jejuni* are crucial virulence factors for the development of GBS. However, there is now a suggestion that the polysaccharide capsule of *C. jejuni* is also an important virulence factor [15]. In two geographically distinct GBS-associated *C. jejuni* strain collections researchers concluded that capsular types HS1/44c, HS2, HS4c, HS19, HS23/36c and HS41 were markers for GBS compared with controls with uncomplicated enteritis [15]. Using MLST they found restricted genetic diversity for strain populations with HS2, HS19 and HS41 capsular types. Thus these capsules may also confer susceptibility to GBS.

Management of GBS involves plasmapheresis and high-dose immunoglobulin therapy plus supportive treatment e.g. mechanical ventilation, prevention of complications such as pneumonia or bed sores and physiotherapy as muscle strength returns. In a Cochrane systematic review of six randomised controlled trials plasmapheresis was found to help speed recovery from GBS without causing significant harm [16]. The authors concluded that there was moderate-quality evidence showing significantly greater improvement with plasmapheresis than supportive care alone in adults with Guillain-Barré syndrome without a significant increase in serious adverse events. They found a small but significant increase in the risk of relapse during the first six to 12 months after onset in patients treated with plasmapheresis exchange compared with patients not undergoing this treatment. Nevertheless, after 12 months, patients who had undergone plasmapheresis were significantly more likely to recover fully and were less likely to suffer severe residual weakness [16]. More recently in a Cochrane review of 12 trials there was moderate quality evidence that, in severe disease, starting intravenous immunoglobulin (IVIg) started two weeks from onset hastened recovery as much as plasmapheresis [17]. There was also moderate quality evidence that administering IVIg after plasmapheresis did not afford significant additional advantage [17]. Finally, often overlooked features of GBS are fatigue, pain and psychological distress, which can have a considerable impact on health-related quality of life (QoL) [18•].

Miller Fisher Syndrome

Miller Fisher syndrome (MFS) is a rare late consequence of *Campylobacter* infection. Essentially, it is a non-paralytic variant of GBS in which patients present with ophthalmoplegia, ataxia and areflexia. Recently a new, simple, clinical classification system has been proposed for GBS, MFS and their subtypes to help to facilitate early clinical diagnosis with a view to starting appropriate immunotherapy as rapidly as possible [19••].

Haemolytic Uraemic Syndrome

Antecedent *Campylobacter* infection has been associated with diarrhoea-related HUS. It is believed to be a rare cause of pulmonary-renal syndrome leading to life-threatening pulmonary haemorrhage [20].

Inflammatory Bowel Disease

There has been considerable debate over the years about a role for *Campylobacter* infection in the aetiology of inflammatory bowel disease (IBD). It has been postulated that in genetically predisposed people gut microbes, in association with a disrupted gastrointestinal epithelium, can fuel and then drive a dysregulated immune response that results in chronic inflammation in the intestine [21,22•]. In a recent systematic review and meta-analysis the association between IBD and a variety of *Campylobacter* spp. was investigated [23••]. In total the sample comprised 519 patients with IBD and 1,133 non-IBD controls. Overall there was an almost three-fold increase in risk of IBD following infection with *Campylobacter* spp. (pooled odds ratio (P-OR) = 2.97 (95% confidence interval (CI) 1.33 - 6.63, p =0.008). In that review *Campylobacter* spp. were confirmed in 39% of patients with IBD compared with 13% of non-IBD controls. On stratification by *Campylobacter* spp. the analyses showed that the organisms chiefly responsible for the observed association with increased risk of IBD were *C. concisus* (P-OR: 3.76, 95% CI 1.46 to 9.70, p value=0.006) and *C. showae* (P-OR: 2.39, 95% CI 1.11 - 5.18, p =0.027) [23••].

Functional Gastrointestinal Disorders

The link between acute gastroenteritis and subsequent post-infectious irritable bowel syndrome (IBS) has been established for some time but there are few studies which have quantified pathogen-specific risk. In a retrospective cohort study of FGID amongst the US military there were statistically significant associations between antecedent *Campylobacter* infection and the risk of developing post-infectious IBS (Adjusted relative risk (aRR) = 2.8 (95% CI 1.9 - 4.1), functional dyspepsia (aRR =

2.0 (95% CI 1.3 - 3.0), functional constipation (aRR = 1.8 (95% CI 1.3 - 2.5) and gastro-oesophageal reflux disease (aRR = 1.7 (95% CI = 1.4 - 2.1) [24••]. In a prospective study risk factors for new-onset irritable bowel syndrome (IBS) among active personnel enrolled in the US military's Millennium Cohort Study significant risk factors included preceding acute gastroenteritis (adjusted hazard ratio (aHR) = 2.05 (95% CI = 1.53 – 2.75), female sex (aHR = 1.96 (95% CI = 1.53 – 2.52) and anxiety syndrome (aHR = 1.74 (95% CI = 1.17 – 2.58)). There was also a dose-response relationship with number of life stressors (1 stressor: aHR = 1.82 (95% CI = 1.37–2.41); 2 stressors: (aHR = 2.86 (95% CI = 2.01 – 4.06); 3 or more stressors: (aHR = 6.69 (95% CI = 4.59 – 9.77. Pre-existing anxiety or depression and acute gastroenteritis interacted with increased IBS risk compared with acute gastroenteritis alone [25••]. The complex interplay between intestinal microbiota and the autonomous nervous system (the so-called “gut-brain axis”) in conjunction with the immune system suggest that the gut-brain axis has a central function in perpetuating irritable bowel syndrome and that the intestinal microbiota play a critical part [26••].

Links between acute gastroenteritis (including *Campylobacter* infection) and FGID other than IBS are also gaining recognition. For example, there is a statistically significant association between functional dyspepsia and preceding acute gastroenteritis (summary odds ratio for post-infectious functional dyspepsia = 2.54 (95% CI = 1.76–3.65) [27•].

Public Health Consequences

Illness burden

The population burden of illness associated with *Campylobacter* infection is very high. On a global scale *Campylobacter* spp. are estimated to cause some 96 million (95% uncertainty interval (UI) 52 - 177 million) cases of foodborne illness [4••]. In the UK there are some 280,000 cases of *Campylobacter* foodborne illness [28] whilst in Canada the estimate is around 145,000 cases [29].

An increasingly common metric for describing the burden of disease associated with foodborne pathogens is the disability-adjusted life year (DALY), which is a useful method for combining loss of life and health due to illness compared with a “perfect” state of health, using time as the common measure. In the US *Campylobacter* infection is estimated to cause about 22 500 DALYs annually [30], whilst in the Netherlands *Campylobacter* spp. are responsible for around 3,600 DALYs per year [31].

Outbreaks

The association between eating undercooked poultry and developing *Campylobacter* infection is well known. However, consuming lightly cooked chicken livers, chicken liver pâté and chicken liver parfait has emerged as important risk factors [32-34]. Recognising this emerging trend in the UK, the Food Standards Agency commissioned research to develop a recipe for manufacturing commercial quantities of chicken liver pâté that reliably kills campylobacters [35•]. Further evidence that cooking practices are responsible for *Campylobacter* cases and outbreaks associated with lightly cooked chicken livers comes from an interdisciplinary study in the UK [36•]. In an online survey most chefs who took part could correctly identify safely cooked chicken livers. However they tended to overestimate consumers’ preference for “pinkness” and so chefs tended to serve chicken livers more lightly cooked than the public would have preferred. Moreover it was estimated that 19%-52% of livers served commercially in the UK do not reach the recommended cooking temperature of 70°C and that predicted *Campylobacter* survival rates in those undercooked livers were between 48% and 98% [36•]. More esoteric causes of recent outbreaks have included contact with wildlife [37], and consumption of raw milk (either intentionally or through failure of pasteurisation) continues to pose risks for *Campylobacter* infection [38,39•].

Sporadic infection

The majority of *Campylobacter* cases are unrelated to outbreaks. Newly identified risk factors for sporadic in recently published case-control studies include contact with garden soil for *C. jejuni* and *C. coli*, and consuming beef (*C. coli* only) [40], and eating cantaloupe and queso fresco (Mexican

cheese) [41]. However, consumption of contaminated poultry continues to feature prominently in the epidemiology of sporadic cases [42,43]. This is not necessarily surprising given the continued high prevalence of contamination of poultry on retail sale [44].

Antimicrobial resistance

Fluoroquinolone and macrolide resistance are well established in campylobacters. Recently a new mechanism for enhanced multidrug resistance in campylobacters has been discovered, which confers remarkably high-level resistance to fluoroquinolones [45••]. This involves the emergence of so-called "super" efflux pump variants that enhance resistance to multiple antimicrobials. This is a resistance-enhancing variant (so-called RE-CmeABC) of the predominant *Campylobacter* efflux pump CmeABC. It also seems that RE-CmeABC can be transferred horizontally [45••].

Economic consequences

Various researchers have monetised the cost of *Campylobacter* infection (Table 2). The estimates of cost vary quite widely reflecting differences in, for example, study design, costing elements included and type of healthcare system. Some researchers included in their cost estimates the impact of long term sequelae whilst others did not. Despite the differences in study design the broad message is the same – namely that *Campylobacter* is a costly infection.

The likely costs of prevention can be hard to estimate but point to the fact that whilst the savings from prevention would accrue mainly to cases and health services the costs would lie elsewhere in government and in industry. Nevertheless in New Zealand, where there has been a considerable effort to reduce *Campylobacter* contamination of poultry flocks the benefit:cost ratio was extremely high [50••]. The beneficial effect of reduced campylobacteriosis to the New Zealand economy was around NZD 57 million per year. So investing in food safety compliance measures at primary production was very worthwhile [50••]. In the absence of such measures in other countries

preventing *Campylobacter* infection still relies on the so-called “4Cs” - thorough cooking and cleaning (including hands and work surfaces), proper chilling and avoiding cross-contamination.

Conclusions

Campylobacter causes considerable morbidity worldwide. Post-infectious sequelae mainly affect the gastrointestinal tract (FGID, IBD), the musculoskeletal system (ReA) and the peripheral nervous system (GBS, MFS) and these sequelae can lead to lifelong disability and reduction in health-related quality of life. The economic costs of *Campylobacter* infection are very high for cases, the healthcare system and for society in general. However, in general, prevention still depends on tried and tested methods i.e. good food (and personal) hygiene.

Key points

- *Campylobacter* is one of the leading bacterial foodborne pathogens worldwide.
- Chronic sequelae post *Campylobacter* infection can be very serious, causing considerable lifelong morbidity.
- There is growing evidence of the importance of the interaction of the gut-brain axis, microbiota and immune system in the pathogenesis of irritable bowel syndrome.
- *C. concisus* and *C. showae* are emerging as potentially important triggers of inflammatory bowel disease.
- Preventing *Campylobacter* infection still relies on the so-called “4Cs” - thorough cooking and cleaning (including hands and work surfaces), proper chilling and avoiding cross-contamination.

Financial support and sponsorship

SJOB is supported by the NIHR Health Protection Research Unit in Gastrointestinal Infections at the University of Liverpool in partnership with Public Health England (PHE), and in collaboration with the Universities of East Anglia and Oxford and the Institute of Food Research. SJO'B is based at the University of Liverpool.

Disclaimer

The views expressed are those of the author and not necessarily those of the NHS, the NIHR, the Department of Health or Public Health England.

References and recommended reading

1. Lastovica AJ, On SLW, Zhang L (2014). The family *Campylobacteraceae*. In: Rosenberg E, DeLong EF, Lory S, Stackbrabdt E, Thompson F (eds) *The Prokaryotes—Deltaproteobacteria and Epsilonproteobacteria*, vol 10, 4th edn. Springer, Berlin, pp 307–335.
 - An authoritative account of campylobacters and related organisms.
2. WHO. WHO estimates of the global burden of foodborne diseases. 2015. WHO: Switzerland.
Available at <
http://apps.who.int/iris/bitstream/10665/199350/1/9789241565165_eng.pdf?ua=1> Date last
accessed October 7 2016.
 - A ground-breaking report that document the global impact of food-related illness.
3. Havelaar AH, Kirk MD, Torgerson PR, Gibb HJ, Hald T, Lake RJ, et al. World Health Organization Global Estimates and Regional Comparisons of the Burden of Foodborne Disease in 2010. *PLoS Med* 2015; 12(12): e1001923.
 - An exceptional synthesis of an extensive set of data to develop global and regional estimates of the burden of foodborne disease due to 31 infectious and chemical hazards
4. Kirk MD, Pires SM, Black RE, Caipo M, Crump JA, Devleesschauwer B, et al. World Health Organization Estimates of the Global and Regional Disease Burden of 22 Foodborne Bacterial, Protozoal, and Viral Diseases, 2010: A Data Synthesis. *PLoS Med* 2015;12(12): e1001921.
 - An outstanding analysis of available data on the burden of foodborne pathogens, emphasising the importance of *Campylobacter* spp.
5. This publication made use of the *Campylobacter* Multi Locus Sequence Typing website (<http://pubmlst.org/campylobacter/>) sited at the University of Oxford (Jolley & Maiden 2010, *BMC Bioinformatics*, 11:595). The development of this site has been funded by the Wellcome Trust.
 - An essential resource for studying the molecular epidemiology of campylobacters.

6. Harvala H, Rosendal T, Lahti E, Engvall EO, Brytting M, Wallensten A, Lindberg A. Epidemiology of *Campylobacter jejuni* infections in Sweden, November 2011–October 2012: is the severity of infection associated with *C. jejuni* sequence type? *Infection Ecology & Epidemiology*. 2016; 6: 10.3402/iee.v6.31079.
 - A well conducted retrospective cohort study demonstrating the importance of underlying illnesses as a major risk factor for hospital admission.
7. Keithlin J, Sargeant J, Thomas MK, Fazil A. Systematic review and meta-analysis of the proportion of *Campylobacter* cases that develop chronic sequelae. *BMC Public Health*. 2014; 14: 1203.
 - A useful review of the chronic sequelae associated with *Campylobacter* infection.
8. Ajene AN, Fischer Walker CL, Black RE. Enteric pathogens and reactive arthritis: a systematic review of *Campylobacter*, *Salmonella* and *Shigella*-associated reactive arthritis. *J Health Popul Nutr*. 2013; 31(3): 299-307.
9. Zautner AE, Johann C, Strubel A, Busse C, Tareen AM, Masanta WO *et al*. Seroprevalence of campylobacteriosis and relevant post-infectious sequelae. *Eur J Clin Microbiol Infect Dis*. 2014; 33(6): 1019-27.
10. Nielsen H, Steffensen R, Ejlersen T. Risk and prognosis of campylobacteriosis in relation to polymorphisms of host inflammatory cytokine genes. *Scand J Immunol*. 2012; 75(4): 449-54.
11. Kuuliala A, Julkunen H, Paimela L, Peltomaa R, Kautiainen H, Repo H, Leirisalo-Repo M. Double-blind, randomized, placebo-controlled study of three-month treatment with the combination of ofloxacin and roxithromycin in recent-onset reactive arthritis. *Rheumatol Int*. 2013; 33(11): 2723-9.
12. Jasti AK, Selmi C, Sarmiento-Monroy JC, Vega DA, Anaya JM, Gershwin ME. Guillain-Barré syndrome: causes, immunopathogenic mechanisms and treatment. *Expert Rev Clin Immunol*. 2016 Jun 21:1-15.

13. Dubey D, Kapotic M, Freeman M, Sawhney A, Rojas JC, Warnack W, Vernino S. Factors contributing to delay in diagnosis of Guillain-Barré syndrome and impact on clinical outcome. *Muscle Nerve*. 2016; 53(3): 384-7.
14. Loshaj-Shala A, Regazzoni L, Daci A, Orioli M, Brezovska K, Panovska AP *et al*. Guillain Barré syndrome (GBS): new insights in the molecular mimicry between *C. jejuni* and human peripheral nerve (HPN) proteins. *J Neuroimmunol*. 2015; 289: 168-76.
15. Heikema AP, Islam Z, Horst-Kreft D, Huizinga R, Jacobs BC, Wagenaar JA *et al*. *Campylobacter jejuni* capsular genotypes are related to Guillain-Barré syndrome. *Clin Microbiol Infect*. 2015; 21(9): 852.e1-9.
16. Raphaël JC, Chevret S, Hughes RAC, Annane D. Plasma exchange for Guillain-Barré syndrome. *Cochrane Database Syst Rev*. 2012; (7): CD001798.
17. Hughes RA, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barré syndrome. *Cochrane Database Syst Rev*. 2014; (9): CD002063.
18. Merkies IS, Kieseier BC. Fatigue, Pain, Anxiety and Depression in Guillain-Barré Syndrome and Chronic Inflammatory Demyelinating Polyradiculoneuropathy. *Eur Neurol*. 2016; 75(3-4): 199-206.
 - An important reminder of the often overlooked features of GBS that impact on health-related quality of life.
19. Wakerley BR, Uncini A, Yuki N; GBS Classification Group. Guillain-Barré and Miller Fisher syndromes--new diagnostic classification. *Nat Rev Neurol*. 2014; 10(9): 537-44.
 - A proposed new clinical classification system to enable neurologists and non-specialists to diagnose GBS and all its variants easily.
20. Bowen EE, Hangartner R, Macdougall I. *Campylobacter*-Associated Hemolytic Uremic Syndrome Associated with Pulmonary-Renal Syndrome. *J Gen Intern Med*. 2016; 31(3): 353-6.
21. Kaakoush NO, Castano-Rodriguez N, Mitchell HM, Man SM. Global epidemiology of *Campylobacter* infection. *Clin Microbiol Rev* 2015; 28: 687–720.

22. Kaakoush NO, Mitchell HM, Man SM. Role of emerging *Campylobacter* species in inflammatory bowel diseases. *Inflamm Bowel Dis* 2014; 20: 2189–97.
- A thorough review of the role of *Campylobacter* spp. in the aetiology of IBD.
23. Castaño-Rodríguez N, Kaakoush NO, Lee WS, Mitchell HM. Dual role of *Helicobacter* and *Campylobacter* species in IBD: a systematic review and meta-analysis. *Gut*. 2015 Oct 27. pii: gutjnl-2015-310545 [E-pub ahead of print].
- A comprehensive, high quality systematic review and meta-analysis demonstrating the increased risk of IBD associated with certain *Campylobacter* species.
24. Porter CK, Choi D, Cash B, Pimentel M, Murray J, May L, Riddle MS. Pathogen-specific risk of chronic gastrointestinal disorders following bacterial causes of foodborne illness. *BMC Gastroenterol*. 2013; 13: 46.
- A robust retrospective epidemiological study that quantifies the pathogen-specific risk of post-infectious functional gastrointestinal disorders.
25. Riddle MS, Welsh M, Porter CK, Nieh C, Boyko EJ, Gackstetter G, Hooper TI. The Epidemiology of Irritable Bowel Syndrome in the US Military: Findings from the Millennium Cohort Study. *Am J Gastroenterol*. 2016; 111(1): 93-104.
- A robust prospective epidemiological study showing significant interactions between acute gastroenteritis, anxiety and depression and subsequent risk of IBS.
26. Raskov H, Burcharth J, Pommergaard HC, Rosenberg J. Irritable bowel syndrome, the microbiota and the gut-brain axis. *Gut Microbes*. 2016; 7(5): 365-83.
- A comprehensive review of recent research on the epidemiology of IBS, the influence of microbiota, the probiota and the gut-brain axis.
27. Futagami S, Itoh T, Sakamoto C. Systematic review with meta-analysis: post-infectious functional dyspepsia. *Aliment Pharmacol Ther*. 2015; 41(2): 177-88.
- A useful systematic review investigating the relationship between acute gastroenteritis and subsequent development of functional dyspepsia.

28. O'Brien SJ, Larose TL, Adak GK, Evans MR, Tam CC; Foodborne Disease Attribution Study Group. Modelling study to estimate the health burden of foodborne diseases: cases, general practice consultations and hospitalisations in the UK, 2009. *BMJ Open*. 2016 Sep 13;6(9):e011119.
29. Thomas MK, Murray R, Flockhart L, Pintar K, Fazil A, Nesbitt A *et al*. Estimates of foodborne illness-related hospitalizations and deaths in Canada for 30 specified pathogens and unspecified agents. *Foodborne Pathog Dis*. 2015; 12(10): 820-7.
30. Scallan E, Hoekstra RM, Mahon BE, Jones TF, Griffin PM. An assessment of the human health impact of seven leading foodborne pathogens in the United States using disability adjusted life years. *Epidemiol Infect*. 2015; 143(13): 2795-804.
31. Mangen MJ, Bouwknegt M, Friesema IH, Haagsma JA, Kortbeek LM, Tariq L *et al*. Cost-of-illness and disease burden of food-related pathogens in the Netherlands, 2011. *Int J Food Microbiol*. 2015; 196: 84-93.
32. Edwards DS, Milne LM, Morrow K, Sheridan P, Verlander NQ, Mulla R *et al*. Campylobacteriosis outbreak associated with consumption of undercooked chicken liver pâté in the East of England, September 2011: identification of a dose-response risk. *Epidemiol Infect*. 2014; 142(2): 352-7.
33. Lahti E, Löfdahl M, Ågren J, Hansson I, Olsson Engvall E. Confirmation of a Campylobacteriosis Outbreak Associated with Chicken Liver Pâté Using PFGE and WGS. *Zoonoses Public Health*. 2016 Jun 23. doi: 10.1111/zph.12272. [Epub ahead of print]
34. Moffatt CR, Greig A, Valcanis M, Gao W, Seemann T, Howden BP, Kirk MD. A large outbreak of *Campylobacter jejuni* infection in a university college caused by chicken liver pâté, Australia, 2013. *Epidemiol Infect*. 2016; 144(14): 2971-2978.
35. Hutchison M, Harrison D, Richardson I, Tchórzewska M. A Method for the Preparation of Chicken Liver Pâté that Reliably Destroys Campylobacters. *Int J Environ Res Public Health*. 2015; 12(5): 4652-69.
- A protocol for manufacturing commercial quantities of chicken liver pâté whilst reliably killing campylobacters.

36. Jones AK, Rigby D, Burton M, Millman C, Williams NJ, Jones TR et al. Restaurant Cooking Trends and Increased Risk for *Campylobacter* Infection. *Emerg Infect Dis*. 2016; 22(7): 1208-15.
- A study demonstrating that chefs' perceptions of how consumers want chicken livers served differs from consumers' views and that the probability of *Campylobacter* survival using chefs' preferred cooking methods is high.
37. Saunders S, Smith K, Schott R, Dobbins G, Scheftel J. Outbreak of Campylobacteriosis Associated with Raccoon Contact at a Wildlife Rehabilitation Centre, Minnesota, 2013. *Zoonoses Public Health*. 2016 Aug 30. doi: 10.1111/zph.12300. [Epub ahead of print]
38. Fernandes AM, Balasegaram S, Willis C, Wimalaratna HM, Maiden MC, McCarthy ND. Partial Failure of Milk Pasteurization as a Risk for the Transmission of *Campylobacter* From Cattle to Humans. *Clin Infect Dis*. 2015; 61(6): 903-9.
39. Giacometti F, Bonilauri P, Amatiste S, Arrigoni N, Bianchi M, Losio MN et al. Human campylobacteriosis related to the consumption of raw milk sold by vending machines in Italy: Quantitative risk assessment based on official controls over four years. *Prev Vet Med*. 2015; 121(1-2): 151-8.
- A timely reminder of the risks of raw milk consumption, especially in view of the recent trend for selling raw milk from vending machines in the UK and elsewhere.
40. Mossong J, Mughini-Gras L, Penny C, Devaux A, Olinger C, Losch S et al. Human Campylobacteriosis in Luxembourg, 2010-2013: A Case-Control Study Combined with Multilocus Sequence Typing for Source Attribution and Risk Factor Analysis. *Sci Rep*. 2016 Feb 10; 6: 20939.
41. Pogreba-Brown K, Baker A, Ernst K, Stewart J, Harris RB, Weiss J. Assessing risk factors of sporadic *Campylobacter* infection: a case-control study in Arizona. *Epidemiol Infect*. 2016; 144(4): 829-39.
42. Bassal R, Ovadia A, Bromberg M, Stein M, Shainberg B, Loewenthal S et al. Risk Factors for Sporadic Infection with *Campylobacter* Spp. among Children in Israel: A Case-Control Study. *Pediatr Infect Dis J*. 2015 Dec 11. [Epub ahead of print].

43. MacDonald E, White R, Mexia R, Bruun T, Kapperud G, Lange H *et al.* Risk Factors for Sporadic Domestically Acquired *Campylobacter* Infections in Norway 2010-2011: A National Prospective Case-Control Study. PLoS One. 2015; 10(10): e0139636.
44. Jorgensen F, Madden RH, Arnold E, Charlett A, Elviss NC. FSA Project FS241044 Survey report: A Microbiological survey of campylobacter contamination in fresh whole UK produced chilled chickens at retail sale (2014-15). 2015. London: Public Health England. Available at <<https://www.food.gov.uk/sites/default/files/campylobacter-retail-survey-final-report.pdf>> Date accessed 10/10/2016.
45. Yao H, Shen Z, Wang Y, Deng F, Liu D, Naren G *et al.* Emergence of a Potent Multidrug Efflux Pump Variant That Enhances *Campylobacter* Resistance to Multiple Antibiotics. MBio. 2016 Sep 20;7(5). pii: e01543-16.
 - An important study identifying a new mechanism for resistance to multiple antimicrobials.
46. Tam CC, O'Brien SJ. Economic Cost of Campylobacter, Norovirus and Rotavirus Disease in the United Kingdom. PLoS One. 2016; 11(2): e0138526.
47. Mangen MJ, Bouwknegt M, Friesema IH, Haagsma JA, Kortbeek LM, Tariq L *et al.* Cost-of-illness and disease burden of food-related pathogens in the Netherlands, 2011. Int J Food Microbiol. 2015; 196: 84-93.
48. Schmutz C, Mäusezahl D, Bless PJ, Hatz C, Schwenkglenks M, Urbinello D. Estimating healthcare costs of acute gastroenteritis and human campylobacteriosis in Switzerland. Epidemiol Infect. 2016 Aug 12:1-15. [Epub ahead of print].
49. Hoffmann S, Macculloch B, Batz M. Economic burden of major foodborne illnesses acquired in the United States: U.S. Department of Agriculture, Economic Research Service, 2015 (Economic Information Bulletin No. 140). Available at <<http://www.ers.usda.gov/media/1837791/eib140.pdf>> Date accessed 10/10/2016.
50. Duncan GE. Determining the health benefits of poultry industry compliance measures: the case of campylobacteriosis regulation in New Zealand. N Z Med J. 2014; 127(1391): 22-37.

- An important assessment of the benefit:cost ratio of reducing campylobacter contamination of poultry at primary production showing a considerable net benefit to the New Zealand economy.

Table 1: Summary of clinically relevant *Campylobacter* species [1]

<i>Campylobacter</i> species	Clinical Features/Associations	Reservoir(s)
<i>C. coli</i>	Gastroenteritis, septicaemia	Dogs, cattle, pigs
<i>C. concisus</i>	Gastroenteritis, periodontal disease, septicaemia; associated with inflammatory bowel disease, Barrett's oesophagus	Humans, dogs, cats
<i>C. curvus</i>	Abscess, gastroenteritis	Humans
<i>C. fetus</i> subspecies (subsp.) <i>fetus</i>	Meningitis, septicaemia, foetal loss, vascular infection	Cattle, dogs, sheep, turtles
<i>C. fetus</i> subsp. <i>venerealis</i>	Septicaemia	Cattle
<i>C. gracilis</i>	Abscess	Dogs, humans
<i>C. hyointestinalis</i> subsp. <i>hyointestinalis</i>	Gastroenteritis, septicaemia	Cattle, hamsters, pigs
<i>C. insulaenigrae</i>	Gastroenteritis, septicaemia	Porpoises, seals
<i>C. jejuni</i> subsp. <i>jejuni</i>	Gastroenteritis, septicaemia, foetal loss, mesenteric adenitis, colitis, myocarditis, reactive arthritis, Guillain-Barré syndrome, Miller Fisher syndrome	Cattle, dogs, poultry, sheep, wild birds
<i>C. jejuni</i> subsp. <i>doylei</i>	Gastroenteritis, septicaemia	Humans, dogs
<i>C. lari</i> subsp. <i>lari</i>	Gastroenteritis, septicaemia	Cats, dogs, chickens, seals

<i>C. rectus</i>	Abscess	Humans
<i>C. showae</i>	Septicaemia, cholangitis; associated with inflammatory bowel disease	Humans, dogs
<i>C. sputorum</i> biovar (bv.) <i>sputorum</i>	Abscess	Humans, cattle, pigs, sheep
<i>C. upsaliensis</i>	Enteritis, septicemia, abortion, abscesses	Cats, dogs, ducks, monkeys
<i>C. ureolyticus</i>	Associated with ulcerative colitis	Cattle

Table 2: Summary of recently published studies estimating the monetary costs of *Campylobacter* infection

Country	Year	Estimated Annual Cost	Estimated cost per case
UK [46]	2008-9	GBP 50 million	GBP 85
Netherlands [47]	2011	EUR 76 million	EUR 706
Switzerland [48]	2012-14	EUR 29–45 million	EUR 63–95
US [49]	2013	USD 1.9 billion	USD 2,283